FDA authorizes trial of stem cell eye treatment

02/16/2012 | Modern Medicine

The FDA has cleared StemCells' experimental neural stem cell therapy for use in a Phase I/II clinical trial for dry age-related macular degeneration. The open-label, dose-escalation trial will involve 16 patients. Results of a preclinical study showed the stem cell treatment can protect photoreceptors and save vision in an animal model of retinal disease.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC